Understanding the evidence

Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway, not a general licence to use cannabis. Under the Misuse of Drugs Act 1975, access is legal only through a prescription from a medical practitioner, and products must meet Good Manufacturing Practice (GMP) standards and be approved by the Ministry of Health. The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated products; the legal product is a manufactured pharmaceutical, and the raw flower, while available, is prescribed and dispensed through a pharmacy, not a dispensary.

This page is the overview. It explains the regulatory frame, the two main cannabinoids, and how to read the evidence. For condition-specific detail, dosing guidance, and product comparisons, the four focused guides own those questions and should be your next stop.

Medicinal cannabis in New Zealand: the regulated pathway

Medicinal cannabis in New Zealand is not a general licence to use cannabis. It is a regulated pharmaceutical pathway under the Misuse of Drugs Act 1975, administered by the New Zealand Ministry of Health through the Medicinal Cannabis Agency (MCA), which sits within Medsafe. The Medicinal Cannabis Scheme, operational since 1 April 2020, sets out how products are manufactured, imported, prescribed and dispensed. The scheme legalises access only when a medical practitioner issues a prescription and the product meets Good Manufacturing Practice (GMP) standards approved by the Ministry of Health (New Zealand Ministry of Health, Medicinal Cannabis Agency, 2020).

The most common misconception is that “legal medicinal cannabis” means a patient can legally smoke raw plant material or buy unregulated products. Under the Misuse of Drugs Act, the legal product is a manufactured pharmaceutical. Raw flower is available, but it is prescribed and dispensed through a pharmacy, not a dispensary. Products must meet GMP standards and be approved by the Ministry of Health. The scheme does not create a general licence to use cannabis; it creates a regulated pharmaceutical pathway. Anyone who buys “medicinal” products outside that pathway is outside the law.

This page is the entry point to the evidence. It explains the regulated pathway, the two main cannabinoids, how to read a product label, and what the research does and does not support. The four focused guides, chronic pain, epilepsy, cancer-related symptoms, and safety, each take one condition or topic and go deeper. This page orients you, then sends you to the right guide.

Medicinal cannabis in New Zealand: the legal baseline

Since 1 April 2020, the Medicinal Cannabis Scheme under the Misuse of Drugs Act 1975 has allowed medical practitioners to prescribe cannabis-based products that meet GMP standards and are approved by the Ministry of Health. The scheme is administered by the Medicinal Cannabis Agency (MCA), which is part of Medsafe, the New Zealand regulator. It does not legalise recreational use, and it does not allow a person to possess or use cannabis without a prescription from a registered medical practitioner.

The legal product is a manufactured pharmaceutical. The raw flower, while available, is prescribed and dispensed through a pharmacy, not a dispensary. The most common mistake newcomers make is assuming that “legal medicinal cannabis” means they can smoke raw plant material or buy unregulated products. Under the Misuse of Drugs Act and the Medicinal Cannabis Scheme (effective 1 April 2020), the legal pathway is a prescription from a medical practitioner, and products must meet GMP standards and be approved by the Ministry of Health (New Zealand Ministry of Health, 2023). The scheme does not permit personal cultivation, supply to others, or possession without a prescription.

For a detailed breakdown of the four main routes into medicinal cannabis, see the four focused guides: the patient pathway, the products, the evidence by condition, and the safety and daily life guide.

How the New Zealand scheme works

New Zealand’s Medicinal Cannabis Scheme was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and came into effect in April 2020. It is administered by the Medicinal Cannabis Agency, which sits inside Medsafe (New Zealand Ministry of Health, 2023). The scheme does not legalise cannabis generally; it legalises a pathway: a medical practitioner can prescribe a product that meets GMP standards and has been notified to the Ministry of Health. Products that meet these standards are listed on the New Zealand Medicinal Cannabis Register, and the prescriber writes a prescription through the normal NZ prescription system. The raw flower is available, but only as a prescribed pharmaceutical product dispensed through a pharmacy, not as a loose “herbal” product.

The legal basis is the Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. Under these, a medical practitioner can prescribe a medicinal cannabis product if they consider it clinically appropriate. The scheme is administered by the Medicinal Cannabis Agency (MCA), which is part of Medsafe, New Zealand’s medicines regulator. Products must meet Good Manufacturing Practice (GMP) and be approved by the Ministry of Health before they can be prescribed. The NZ Formulary lists the approved products and provides prescribing guidance for clinicians.

The evidence base for medicinal cannabis is still developing. In New Zealand, the Ministry of Health and the NZ Formulary rely on systematic reviews and peer-reviewed clinical guidance, not anecdote. For chronic pain, the strongest evidence supports a modest effect; for refractory epilepsy, the evidence is strongest for CBD-predominant products, particularly in specific paediatric syndromes. For anxiety and sleep, evidence is mixed; some patients benefit, but the data are not robust enough for first-line use. Cancer-related nausea and appetite loss have moderate evidence, but again not as first-line therapy.

The scheme requires a prescription from a medical practitioner, and the product must be a “controlled drug” approved under the Misuse of Drugs Act. New Zealand’s Medicinal Cannabis Scheme, administered by the Medicinal Cannabis Agency (part of Medsafe), sets GMP standards and product approval requirements. The Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, effective 1 April 2020, created the framework. The NZ Formulary lists cannabis products and prescribers are encouraged to follow its guidance.

New Zealand law does not allow smoking raw plant material; the legal products are manufactured pharmaceuticals (flower for vaporisation, oils, capsules, or powders). Flower is available but must be prescribed and dispensed through a pharmacy. The scheme does not permit home cultivation, possession without a prescription, or supply outside the regulated pathway. The Ministry of Health, via the Medicinal Cannabis Agency, oversees licensing and quality.

Key facts for patients: - Access requires a prescription from a medical practitioner. - Products must meet GMP standards and be approved by the Ministry of Health under the Medicinal Cannabis Scheme. - The scheme legalises access via prescription, not general use. - Raw plant material for smoking is not a “medicinal product” under the scheme, though some prescribed flower is available for vaporisation. - The Misuse of Drugs Act 1975 and Misuse of Drugs (Medicinal Cannabis) Regulations 2019 govern the scheme. - The Medicinal Cannabis Agency (MCA) issues licences and enforces quality standards.

HOW_TO_CHOOSE_AMONG_THE_OPTIONS: Choosing among the many medicinal cannabis products in New Zealand can feel overwhelming. This guide gives you a decision path. Work through it in order.

Step 1: Confirm the legal pathway. Under the Misuse of Drugs Act 1975, cannabis is a controlled drug, but the Medicinal Cannabis Scheme (established under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019) allows a medical practitioner to prescribe a manufactured cannabis product that meets GMP standards and is approved by the Ministry of Health. If a product is not on the scheme, it is not legal for medicinal use. Check the product is listed on the Medicinal Cannabis Agency’s product list before you proceed. If you are a patient, this step is about knowing the legal boundaries, not choosing a product.

Step 2: Identify the condition and the outcome. Cannabis is not a single drug; it is a family of products with different ratios of THC and CBD, different forms, and different onset/duration profiles. The evidence is condition-specific. For example, systematic reviews from the US National Academies (2017) found moderate evidence for chronic pain and for nausea from chemotherapy, but not for most other conditions. The NZ Formulary lists cannabis products for chronic pain, chemotherapy-induced nausea and vomiting, and refractory epilepsy in children and adults, but does not endorse it as a first-line treatment for any condition. Name the condition, the outcome you are targeting, and the preparation before comparing products.

THE FOUR GUIDES: - /evidence/conditions/ - /evidence/outcomes/ - /evidence/preparations/ - /evidence/quality/